The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Lutskaya D.A.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Dzhibladze T.A.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Petelin D.S.

Sechenov First Moscow State Medical University (Sechenov University)

Sorokina O.Yu.

Sechenov First Moscow State Medical University (Sechenov University)

Semin S.A.

Klinika «Spasenie»

Volel’ B.A.

I.M. Sechenov First Moscow State Medical University (Sechenov University);
Mental Health Research Center

The role of neurosteroids in the development of premenstrual dysphoric disorder

Authors:

Lutskaya D.A., Dzhibladze T.A., Petelin D.S., Sorokina O.Yu., Semin S.A., Volel’ B.A.

More about the authors

Journal: Russian Bulletin of Obstetrician-Gynecologist. 2023;23(3): 56‑63

DOI: 10.17116/rosakush20232303156

Read: 1980 times

Download PDF (RU)
Contact the author
Table of contents

THE ROLE OF NEUROSTEROIDS IN THE DEVELOPMENT OF PREMENSTRUAL DYSPHORIC DISORDER
THE ROLE OF NEUROSTEROIDS IN THE DEVELOPMENT OF PREMENSTRUAL DYSPHORIC DISORDER

To cite this article:

Lutskaya DA, Dzhibladze TA, Petelin DS, Sorokina OYu, Semin SA, Volel’ BA. The role of neurosteroids in the development of premenstrual dysphoric disorder. Russian Bulletin of Obstetrician-Gynecologist. 2023;23(3):56‑63. (In Russ.)
https://doi.org/10.17116/rosakush20232303156

Подписка 2026 Российский вестник акушера-гинеколога (Russian Bulletin of Obstetrician-Gynecologist)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Evaluation of hormonal function of the placenta in pregnant women with geni­tal vari­cose veins. Russian Bulletin of Obstetrician-Gynecologist. 2025;(3):73-78
Evaluation of prognostic factors of preterm birth. Russian Journal of Human Reproduction. 2025;(2):37-43
Vari­cose veins in chro­nic expe­riment. Piro­gov Russian Journal of Surgery. 2025;(7):16-23
Abstract:

Premenstrual dysphoric disorder (PMDD), associated with the female reproductive cycle, occurs during the luteal phase of the menstrual cycle and presents affective and somatic symptoms and significantly reduces women’s quality of life by impairing their daily activities. The high prevalence of PMDD necessitates a search for the mechanisms of this disorder in order to select more effective and safer etiotropic therapies to correct abnormalities in pathogenesis. This review provides evidence for the involvement of the progesterone which converts to neurosteroid in the brain, namely allopregnanolone, and the altered sensitivity of the GABAergic system in the development of PMDD. Currently, there is a prospect of searching for etiotropic therapy in PMDD, positively influencing on one of three mechanisms of allopregnanolone action: the use of allopregnanolone antagonists, inhibition of progesterone conversion to allopregnanolone and restoration of sensitivity of the GABAergic system.

Keywords:

premenstrual dysphoric disorder
neurosteroids
allopregnanolone
progesterone
GABAergic receptors
premenstrual syndrome
dysphoria

Authors:

Lutskaya D.A.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Dzhibladze T.A.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Petelin D.S.

Sechenov First Moscow State Medical University (Sechenov University)

Sorokina O.Yu.

Sechenov First Moscow State Medical University (Sechenov University)

Semin S.A.

Klinika «Spasenie»

Volel’ B.A.

I.M. Sechenov First Moscow State Medical University (Sechenov University);
Mental Health Research Center

Received:

14.03.2023

Accepted:

20.03.2023

Close metadata

References:

  1. Volel BA, Ragimova AA, Kuznetsova IV, Burchakov DI. Modern ideas about stress-dependent menstrual cycle disorders. Akusherstvo i ginekologiya. 2016;12:34-40. (In Russ.). https://doi.org/10.18565/aig.2016.12.34-40
  2. Ragimova AA, Ivanov SV. Clinical study of postpartum depression in schizophrenia. Psikhicheskie rasstroistva v obshchei meditsine. 2017;1-2:4-11. (In Russ.).
  3. Volel’ BA, Yan’shina TP. Involutional hysteria within the dynamics of personality disorders. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2005;8:18-23. (In Russ.).
  4. Mishra S, Elliott H, Marwaha R. Premenstrual dysphoric disorder. StatPearls. Treasure Island, FL: StatPearls Publishing 2022. https://www.ncbi.nlm.nih.gov/books/NBK532307/
  5. Carlini SV, Lanza di Scalea T, McNally ST, Lester J, Deligiannidis KM. Management of premenstrual dysphoric disorder: A scoping review. Int J Women’s Health. 2022;14:1783-1801. https://doi.org/10.2147/IJWH.S297062
  6. Loginova KB, Dyukova GM, Dobrokhotova YuE, Danilov AB. Premenstrual dysphoric disorders in women of Russian Federation and risk factors for their development. Epidemiological study of1,326 women. Meditsinskii alfavit. 2019;1:2:43-46. (In Russ.). https://doi.org/10.33667/2078-5631-2019-1-2(377)-43-46
  7. Chumpalova P, Iakimova R, Stoimenova-Popova M, Aptalidis D, Pandova M, Stoyanova M, Fountoulakis KN. Prevalence and clinical picture of premenstrual syndrome in females from Bulgaria. Ann Gen Psychiatry. 2020;19:1:1-7.  https://doi.org/10.1186/s12991-019-0255-1
  8. Dutta A, Sharma A. Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in India: A systematic review and meta-analysis. Health Promot Perspect. 2021;11:2:161.  https://doi.org/10.34172/hpp.2021.20
  9. Schatz DB, Hsiao M-C, Liu C-Y. Premenstrual dysphoric disorder in East Asia: a review of the literature. Int J Psychiatry Med. 2012;43:365-380.  https://doi.org/10.2190/PM.43.4.f
  10. Shehadeh J, Hamdan-Mansour A. Prevalence and association of premenstrual syndrome and premenstrual dysphoric disorder with academic performance among female university students. Perspect Psychiatric Care. 2017;54:2;176-184.  https://doi.org/10.1111/ppc.12219
  11. Gao M, Gao D, Sun H, Cheng X, An L, Qiao M. Trends in research related to premenstrual syndrome and premenstrual dysphoric disorder from 1945 to 2018: a bibliometric analysis. Front Public Health. 2021;9:596128.
  12. Zhilyaeva TV. Premenstrual mood disorders: pathogenesis, diagnostic criteria and treatment (a review). Problemy reproduktsii. 2015;21:4:76-85. (In Russ.). https://doi.org/10.17116/repro201521476-85
  13. Prasad D, Wollenhaupt-Aguiar B, Kidd KN, de Azevedo Cardoso T, Frey BN. Suicidal risk in women with premenstrual syndrome and premenstrual dysphoric disorder: a systematic review and meta-analysis. J Women’s Health. 2021;30:1693-1707. https://doi.org/10.1089/jwh.2021.0185
  14. Smulevich AB. Depression in general medicine: a guide for doctors. M.: Meditsinskoe informatsionnoe agentstvo; 2007;64-66. (In Russ.).
  15. Tiranini L, Nappi RE. Recent advances in understanding/management of premenstrual dysphoric disorder/premenstrual syndrome. Faculty Rev. 2022;11:11.  https://doi.org/10.12703/r/11-11
  16. Carlini SV, Deligiannidis KM. Evidence-Based treatment of premenstrual dysphoric disorder: a concise review. J Clin Psychiatry. 2020;81:6789. https://doi.org/10.4088/JCP.19ac13071
  17. Rapkin AJ, Korotkaya Y, Taylor KC. Contraception counseling for women with premenstrual dysphoric disorder (PMDD): current perspectives. Open Access J Contraception. 2019;10:27-39.  https://doi.org/10.2147/OAJC.S183193
  18. Schmidt PJ, Martinez PE, Nieman LK, Koziol DE, Thompson KD, Schenkel L, Wakim PG, Rubinow DR. Premenstrual dysphoric disorder symptoms following ovarian suppression: triggered by change in ovarian steroid levels but not continuous stable levels. Am J Psychiatry. 2017;174:980-989.  https://doi.org/10.1176/appi.ajp.2017.16101113
  19. Ismaili E, Walsh S, O’Brien PMS, Bäckström T, Brown C, Dennerstein L, Eriksson E, Freeman EW, Ismail KMK, Panay N, Pearlstein T, Rapkin A, Steiner M, Studd J, Sundström-Paromma I, Endicott J, Epperson CN, Halbreich U, Reid R, Rubinow D, Schmidt P, Yonkers K. Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): auditable standards for diagnosis and management of premenstrual disorder. Arch Womens Ment Health. 2016;19:953-958.  https://doi.org/10.1007/s00737-016-0631-7
  20. Hantsoo L, Riddle J. Treatment of premenstrual dysphoric disorder (PMDD): advances and challenges. Arch Women’s Mental Health. 2021;19:953-958.  https://doi.org/10.1016/j.ypsc.2021.05.009
  21. Halbreich U. Selective serotonin reuptake inhibitors and initial oral contraceptives for the treatment of PMDD: effective but not enough. CNS Spectrums. 2008;13:566-572.  https://doi.org/10.1017/S1092852900016849
  22. Kulikov IA, Ovsyannikova TV. Premenstrual syndrome: possibility of therapy. Gynekologiya. 2014;16:2:18-20. (In Russ.).
  23. Tiemstra JD, Patel K. Hormonal therapy in the management of premenstrual syndrome. J Am Board Family Pract. 1998;11:378-381.  https://doi.org/10.3122/15572625-11-5-378
  24. Kancheva Landolt N, Ivanov K. Short report: cognitive behavioral therapy — a primary mode for premenstrual syndrome management: systematic literature review. Psychol, Health Med. 2021;26:1282-1293. https://doi.org/10.1080/13548506.2020.1810718
  25. Itriyeva K. Premenstrual syndrome and premenstrual dysphoric disorder in adolescents. Curr Problems Pediatr Adolesc Health Care. 2022;52:101187. https://doi.org/10.1016/j.cppeds.2022.101187
  26. Pereira D, Pessoa AR, Madeira N, Macedo A, Pereira AT. Association between premenstrual dysphoric disorder and perinatal depression: a systematic review. Arch Women’s Mental Health. 2022;25.1:61-70.  https://doi.org/10.1007/s00737-021-01177-6
  27. Guennoun R. Progesterone in the brain: hormone, neurosteroid and neuroprotectant. Int J Mol Scie. 2020;21:5271. https://doi.org/10.3390/ijms21155271
  28. Yilmaz C, Karali K, Fodelianaki G, Gravanis A, Chavakis T, Charalampopoulos I, et al. Neurosteroids as regulators of neuroinflammation. Front Neuroendocrinol. 2019;55:100788. https://doi.org/10.1016/j.yfrne.2019.100788
  29. Sigel E, Ernst M. The Benzodiazepine binding sites of GABAA receptors. Trends Pharmacol Scie. 2018;39:659-671.  https://doi.org/10.1016/j.tips.2018.03.006
  30. Rang R, Ritter JM, Flower RJ, Henderson G. Rang & Dale Farmacologia. Elsevier Brasil. 2015;498. 
  31. Chen ZW, Bracamontes JR, Budelier MM, Germann AL, Shin DJ, Kathiresan K, Qian M-X, Manion B, Cheng WWL, Reichert DE, Akk G, Covey DF, Evers AS. Multiple functional neurosteroid binding sites on GABAA receptors. PLoS Biol. 2019;17:3:e3000157. https://doi.org/10.1371/journal.pbio.3000157
  32. Slyepchenko A, Minuzzi L, Frey BN. Comorbid premenstrual dysphoric disorder and bipolar disorder: a review. Front Psychiatry. 2021;12:719241. https://doi.org/10.3389/fpsyt.2021.719241
  33. Bäckström T, Bixo M, Strömberg J. GABAA receptor-modulating steroids in relation to women’s behavioral health. Curr Psychiatry Rep. 2015;17:92.  https://doi.org/10.1007/s11920-015-0627-4
  34. Martinez PE, Rubinow DR, Nieman LK, Koziol DE, Morrow AL, Schiller CE, Cintron D, Thompson KD, Khin KK, Schmidt PJ. 5α-Reductase Inhibition Prevents the luteal phase increase in plasma allopregnanolone levels and mitigates symptoms in women with premenstrual dysphoric disorder. Neuropsychopharmacology. 2016;41:1093-1102. https://doi.org/10.1038/npp.2015.246
  35. Bäckström T, Ekberg K, Hirschberg AL, Bixo M, Epperson CN, Briggs P, Panay N, O’Brien S. A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder. Psychoneuroendocrinology. 2021;133:105426. https://doi.org/10.1016/j.psyneuen.2021.105426
  36. Gonzalez J, Upadhyaya VD, Manna ZT, Sharma AR, Christopher J, Douedi S, Sen S. Paradoxical excitation following intravenous lorazepam administration for alcohol withdrawal — a case presentation and literature review. J Pharm Pract. 2022; 8971900221097182. https://doi.org/10.1177/08971900221097182
  37. Reddy MSS, Achary U, Harbishettar V, Sivakumar PT, Varghese M. Paradoxical reaction to benzodiazepines in elderly — Case series. Asian J Psychiatry. 2018;35:8-10.  https://doi.org/10.1016/j.ajp.2018.04.037
  38. McCarroll MN, Gendelev L, Kinser R, Taylor J, Bruni G, Myers-Turnbull D, Helsell C, Carbajal A, Rinaldi C, Kang HJ, Gong JH, Sello JK, Tomita S, Peterson RT, Keiser MJ, Kokel D. Zebrafish behavioural profiling identifies GABA and serotonin receptor ligands related to sedation and paradoxical excitation. Nature Communications. 2019;10:1:4078. https://doi.org/10.1038/s41467-019-11936-w
  39. Kirkpatrick D, Smith T, Kerfeld M, Ramsdell T, Sadiq H, Sharma A. Paradoxical reaction to alprazolam in an elderly woman with a history of anxiety, mood disorders, and hypothyroidism. Case Reports Psychiatry. 2016;6748947. https://doi.org/10.1155/2016/6748947
  40. Tae CH, Kang KJ, Min BH, Ahn JH, Kim S, Lee JH, Rhee PL, Kim JJ. Paradoxical reaction to midazolam in patients undergoing endoscopy under sedation: Incidence, risk factors and the effect of flumazenil. Digest Liver Dis. 2014;46:8:710-715.  https://doi.org/10.1016/j.dld.2014.04.007
  41. Kuypers K, Verkes RJ, van den Brink W, van Amsterdam J, Ramaekers JG. Intoxicated aggression: Do alcohol and stimulants cause dose-related aggression? A review. Eur Neuropsychopharmacol. 2020;30:114-147.  https://doi.org/10.1016/j.euroneuro.2018.06.001
  42. Mincheva G, Gimenez-Garzo C, Izquierdo-Altarejos P, Martinez-Garcia M, Doverskog M, Blackburn TP, Hällgren A, Bäckström T, Llansola M, Felipo V. Golexanolone, a GABAA receptor modulating steroid antagonist, restores motor coordination and cognitive function in hyperammonemic rats by dual effects on peripheral inflammation and neuroinflammation. CNS Neurosci Ther. 2022;28:11:1861-1874. https://doi.org/10.1111/cns.13926
  43. Bixo M, Johansson M, Timby E, Michalski L, Bäckström T. Effects of GABA active steroids in the female brain with a focus on the premenstrual dysphoric disorder. J Neuroendocrinol. 2018;30:2:e12553. https://doi.org/10.1111/jne.12553
  44. Reddy DS, Estes WA. Clinical Potential of Neurosteroids for CNS Disorders. Trends Pharmacol Scie. 2016;37:7:543-561.  https://doi.org/10.1016/j.tips.2016.04.003
  45. Sundström I, Ashbrook D, Bäckström T. Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Psychoneuroendocrinology. 1997;22.1:25-38.  https://doi.org/10.1016/s0306-4530(96)00035-2
  46. Evans SM, Haney M, Levin FR, Foltin RW, Fischman MW. Mood and performance changes in women with premenstrual dysphoric disorder: acute effects of alprazolam. Neuropsychopharmacology. 1998;19:499-516.  https://doi.org/10.1016/S0893-133X(98)00064-5
  47. Evans SM, Levin FR. Response to alcohol in women: role of the menstrual cycle and a family history of alcoholism. Drug Alcohol Depend. 2011;114:1:18-30.  https://doi.org/10.1016/j.drugalcdep.2010.09.001
  48. Mello NK, Mendelson JH, Lex BW. Alcohol use and premenstrual symptoms in social drinkers. Psychopharmacology. 1990;101:448-455.  https://doi.org/10.1007/BF02244221
  49. Hernandez GD, Brinton RD. Allopregnanolone: regenerative therapeutic to restore neurological health. Neurobiol Stress. 2022;21:100502. https://doi.org/10.1016/j.ynstr.2022.100502
  50. Pierce SR, Germann AL, Evers AS, Steinbach JH, Akk G. Reduced Activation of the synaptic-type GABAA receptor following prolonged exposure to low concentrations of agonists: relationship between tonic activity and desensitization. Mol Pharmacol. 2020;98:6:762-769.  https://doi.org/10.1124/molpharm.120.000088
  51. Maity S, Wray J, Coffin T, Nath R, Nauhria S, Sah R, Waechter R, Ramdass P, Nauhria S. Academic and social impact of menstrual disturbances in female medical students: a systematic review and meta-fnalysis. Front Med. 2022;9:821908. https://doi.org/10.3389/fmed.2022.821908
  52. Gallo AT, Hulse GK. A theory of the anxiolytic action of flumazenil in anxiety disorders. J Psychopharmacol. 2022;36:4:439-448.  https://doi.org/10.1177/02698811221082466
  53. Benini A, Gottardo R, Chiamulera C, Bertoldi A, Zamboni L, Lugoboni F. Continuous infusion of flumazenil in the management of benzodiazepines detoxification. Front Psychiatry. 2021;12:646038. https://doi.org/10.3389/fpsyt.2021.646038
  54. Hantsoo L, Epperson CN. Allopregnanolone in premenstrual dysphoric disorder (PMDD): Evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle. Neurobiol Stress. 2020;12:100213. https://doi.org/10.1016/j.ynstr.2020.100213
  55. Gracia CR, Freeman EW, Sammel MD, Lin H, Sheng L, Frye C. Allopregnanolone levels before and after selective serotonin reuptake inhibitor treatment of premenstrual symptoms. J Clin Psychopharmacol. 2009;29:4:403-405.  https://doi.org/10.1097/JCP.0b013e3181ad8825
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.